Program
Autologous Tumor-infiltrating Lymphocytes HS-IT101
Also written as “HS-IT101 Injection” and “HS-IT101 monotherapy”.
Its studies are mostly in Melanoma · Carcinoma, Renal Cell, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hangzhou Huasai Biomedicine | 21 open or running | phase 1since Apr 15, 2025 | Apr 15, 2025 | Aug 2028phase 1 · NCT07770802 |
| Qingdao Sino-Cell Biomedicine | 11 open or running | phase 1since Mar 19, 2024 | Mar 19, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 19, 2024First study: phase 1 study in Solid TumorNew to Qingdao Sino-Cell BiomedicineQingdao Sino-Cell Biomedicine · NCT06342336 · 44 planned · China
- Apr 15, 2025Hangzhou Huasai Biomedicine’s first study: phase 1 study in Advanced MelanomaNew to Hangzhou Huasai BiomedicineHangzhou Huasai Biomedicine · NCT06941818 · 5 enrolled · China
- Aug 13, 2026Phase 1 study in Carcinoma, Renal CellHangzhou Huasai Biomedicine · NCT07770802 · 15 planned · China
Ahead
- Aug 2028Primary completion: phase 1 study in Carcinoma, Renal CellHangzhou Huasai Biomedicine · NCT07770802
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07770802Carcinoma, Renal Cell · China | 1 | Recruiting | Hangzhou Huasai Biomedicine | Aug 2028 | 15 |
| NCT06941818Advanced Melanoma · China | 1 | Completed | Hangzhou Huasai Biomedicine | Feb 20, 2026 | 5 |
| NCT06342336Solid Tumor · China | 1 | Recruiting | Qingdao Sino-Cell Biomedicine | Mar 31, 2026 | 44 |
How it is read
Names in the registry
- “HS-IT101 Injection”, 2 entries
- “HS-IT101 monotherapy”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 1 study
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.